RayKnowChina Research Map
Shortlist

RecruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Pulmonary Hospital; 8 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 20 years to 79 years; sex: all

    Registered eligibility fields

  2. Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;

    Exclusion criterion 10

  3. Tumor size <= 2cm on preoperative CT scan;

    Inclusion criterion 2

    Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);

    Inclusion criterion 4

  4. Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy);

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04937283, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patient aged 20-79 years old, both male or female;
  • Tumor size <= 2cm on preoperative CT scan;
  • Peripheral solitary nodule or the associated lesion is MIA or less invasive lesion;
  • Preoperative CT indicated that the nodules were non-pure glass nodules (consolidation to tumor ratio >= 0.25);
  • Intraoperative frozen section confirmed invasive lung adenocarcinoma with micropapillary and solid subtype negative (<= 5%);
  • Intraoperative frozen section indicated the resection margins was free of tumor cells;
  • Lung function could withstand both lung segmentectomy and lobectomy (FEV1 > 1.5L or FEV1% >= 60%);
  • Eastern Cooperative Oncology Group, 0 to 2;
  • Volunteer to participate the trial and sign the informed consent, able to comply with the follow-up plan and other program requirements.

Exclusion Criteria:

  • Radiological pure ground glass nodules (consolidation to tumor ratio < 0.25);
  • The nodule is close to the lung hilus and is unable to perform segmentectomy;
  • Intraoperative frozen section confirmed with micropapillary and solid subtype positive (> 5%);
  • Intraoperative frozen section confirmed adenocarcinoma in situ and minimally invasive adenocarcinoma;
  • Preoperative imaging examination or EBUS indicated lymph node positive metastasis;
  • Preoperative imaging examination revealed distant metastasis;
  • Patients with severe damage to heart, liver and kidney function (grade 3 \~ 4, ALT and/or AST over 3 times the normal upper limit, Cr over the normal upper limit);
  • Patients with other malignant tumors;
  • Pregnant, planned pregnancy and lactating female patients (urine HCG>2500IU/L is diagnosed as early pregnancy);
  • Prior chemotherapy, radiation therapy or any other therapies were performed; 12 participated in other tumors within three months of relevant clinical subjects;
  • Those who have participated in other tumor-related clinical trials within three months;
  • Those are not suitable for participating in trials according to investigator's assessment.

Quoted from ClinicalTrials.gov, NCT04937283, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04937283, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04937283